Syros Pharmaceuticals Inc...
0.24
0.00 (1.01%)
At close: Jan 15, 2025, 3:59 PM
0.22
-6.59%
After-hours Jan 15, 2025, 05:04 PM EST
undefined%
Bid 0.22
Market Cap 6.39M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.07
PE Ratio (ttm) -0.08
Forward PE n/a
Analyst Hold
Ask 0.24
Volume 1,669,652
Avg. Volume (20D) 9,687,409
Open 0.23
Previous Close 0.24
Day's Range 0.21 - 0.25
52-Week Range 0.18 - 7.96
Beta undefined

About SYRS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acu...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2016
Employees 68
Stock Exchange NASDAQ
Ticker Symbol SYRS

Analyst Forecast

According to 5 analyst ratings, the average rating for SYRS stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 1159.45% from the latest price.

Buy 20.00%
Hold 80.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Syros Pharmaceuticals Inc. is scheduled to release its earnings on Mar 26, 2025, before market opens.
Analysts project revenue of $450.00K, reflecting a 16.28% YoY growth and earnings per share of -0.74, making a -66.06% decrease YoY.
1 month ago · Source
+39.24%
Syros Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription
1 month ago · Source
-23.33%
Syros Pharmaceuticals shares are trading lower after the company announced it gave notice to QIAGEN Manchester of its election to terminate the Master Collaboration Agreement.